ACS Chemical Neuroscience Molecule Spotlight on Suvorexant

作者：Hopkins Corey R^*

来源：ACS Chemical Neuroscience, 2012, 3(9): 647-648.

DOI：10.1021/cn300086a

• Sleep
• insomnia
• novel mechanism
• orexin antagonist
• bioavailability (F)

Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

• 出版日期2012-9